Does the 56-day semaglutide in-use window apply to every semaglutide preparation?
No. That window is label-backed for specific approved products and should not be silently generalized to every reconstituted research setup.
FAQ Deep Dive
Semaglutide Reconstitution FAQ
Semaglutide is one of the easiest peptides to over-generalize because branded pens have stronger stability evidence than most research vials. This FAQ keeps those evidence tiers separated.
Why does the calculator show a 5 mg vial / 2 mL / 0.5 mg example?
It is a visible, sourced math example for concentration context. The example exists to show conversion logic rather than to recommend a particular workflow.
How many units is 0.5 mg at 2.5 mg/mL?
At 2.5 mg/mL, each U-100 unit contains 0.025 mg. A 0.5 mg target therefore equals 20 units.
Should semaglutide stay refrigerated after first use?
Approved semaglutide labeling allows a defined in-use window at room temperature or refrigerated storage for the branded product. Research-vial workflows should still be treated as formulation-specific rather than assumed identical.
Related reading
Evidence used here
- Ozempic FDA label
Supports the semaglutide labeled in-use window and do-not-freeze wording for the branded product.
- STEP-1 trial
Supports trial-context discussion of semaglutide outcomes, not generalized vial stability.